Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia

Ayalew Tefferi, T. Jiménez, L. A. Gray, R. A. Mesa, M. G. Chen

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective: To describe the experience with liver irradiation in advanced cases of myelofibrosis with myeloid metaplasia (MMM). Methods: Over a 20-yr period, 14 patients with MMM were treated with a total of 25 courses of liver, abdominal, or abdominal and pelvic irradiation for symptomatic hepatomegaly with (5 patients) or without (9 patients) ascites. All 14 patients had advanced disease and 11 (79%) had previous splenectomy. The median radiation therapy (RT) dose per course was 150 cGy (range 50-1000) administered at a median of six fractions. Four patients received two to six courses. Results: Twelve of the 14 patients (86%) had a transient (median 3 months) subjective response from RT. However, in only 35% of these was there a transient (median 3 months) decrease in palpable liver size. Four of the five patients with ascites experienced a short-term response from RT. Eight of the 13 patients suitable for evaluation (62%) had treatment-associated cytopenia, often in the form of anemia and/or thrombocytopenia. At last follow-up, 10 patients (71%) had died after a median of 7 months (range 0.1-23) and 4 were alive at 3, 20, 33, and 57 months after RT. Conclusions: Low-dose abdominal RT for symptomatic hepatomegaly or ascites associated with advanced-stage MMM is myelosuppressive and provides only temporary and mainly subjective and short-lived relief.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalEuropean Journal of Haematology
Volume66
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Primary Myelofibrosis
Hepatomegaly
Radiotherapy
Ascites
Liver
Splenectomy
Thrombocytopenia
Anemia

Keywords

  • Hepatomegaly
  • Myelofibrosis with myeloid metaplasia
  • Radiation therapy
  • Splenectomy

ASJC Scopus subject areas

  • Hematology

Cite this

Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. / Tefferi, Ayalew; Jiménez, T.; Gray, L. A.; Mesa, R. A.; Chen, M. G.

In: European Journal of Haematology, Vol. 66, No. 1, 2001, p. 37-42.

Research output: Contribution to journalArticle

Tefferi, Ayalew ; Jiménez, T. ; Gray, L. A. ; Mesa, R. A. ; Chen, M. G. / Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. In: European Journal of Haematology. 2001 ; Vol. 66, No. 1. pp. 37-42.
@article{5282769bb7e1472e8bda00a7e46f34e7,
title = "Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia",
abstract = "Objective: To describe the experience with liver irradiation in advanced cases of myelofibrosis with myeloid metaplasia (MMM). Methods: Over a 20-yr period, 14 patients with MMM were treated with a total of 25 courses of liver, abdominal, or abdominal and pelvic irradiation for symptomatic hepatomegaly with (5 patients) or without (9 patients) ascites. All 14 patients had advanced disease and 11 (79{\%}) had previous splenectomy. The median radiation therapy (RT) dose per course was 150 cGy (range 50-1000) administered at a median of six fractions. Four patients received two to six courses. Results: Twelve of the 14 patients (86{\%}) had a transient (median 3 months) subjective response from RT. However, in only 35{\%} of these was there a transient (median 3 months) decrease in palpable liver size. Four of the five patients with ascites experienced a short-term response from RT. Eight of the 13 patients suitable for evaluation (62{\%}) had treatment-associated cytopenia, often in the form of anemia and/or thrombocytopenia. At last follow-up, 10 patients (71{\%}) had died after a median of 7 months (range 0.1-23) and 4 were alive at 3, 20, 33, and 57 months after RT. Conclusions: Low-dose abdominal RT for symptomatic hepatomegaly or ascites associated with advanced-stage MMM is myelosuppressive and provides only temporary and mainly subjective and short-lived relief.",
keywords = "Hepatomegaly, Myelofibrosis with myeloid metaplasia, Radiation therapy, Splenectomy",
author = "Ayalew Tefferi and T. Jim{\'e}nez and Gray, {L. A.} and Mesa, {R. A.} and Chen, {M. G.}",
year = "2001",
doi = "10.1034/j.1600-0609.2001.00342.x",
language = "English (US)",
volume = "66",
pages = "37--42",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia

AU - Tefferi, Ayalew

AU - Jiménez, T.

AU - Gray, L. A.

AU - Mesa, R. A.

AU - Chen, M. G.

PY - 2001

Y1 - 2001

N2 - Objective: To describe the experience with liver irradiation in advanced cases of myelofibrosis with myeloid metaplasia (MMM). Methods: Over a 20-yr period, 14 patients with MMM were treated with a total of 25 courses of liver, abdominal, or abdominal and pelvic irradiation for symptomatic hepatomegaly with (5 patients) or without (9 patients) ascites. All 14 patients had advanced disease and 11 (79%) had previous splenectomy. The median radiation therapy (RT) dose per course was 150 cGy (range 50-1000) administered at a median of six fractions. Four patients received two to six courses. Results: Twelve of the 14 patients (86%) had a transient (median 3 months) subjective response from RT. However, in only 35% of these was there a transient (median 3 months) decrease in palpable liver size. Four of the five patients with ascites experienced a short-term response from RT. Eight of the 13 patients suitable for evaluation (62%) had treatment-associated cytopenia, often in the form of anemia and/or thrombocytopenia. At last follow-up, 10 patients (71%) had died after a median of 7 months (range 0.1-23) and 4 were alive at 3, 20, 33, and 57 months after RT. Conclusions: Low-dose abdominal RT for symptomatic hepatomegaly or ascites associated with advanced-stage MMM is myelosuppressive and provides only temporary and mainly subjective and short-lived relief.

AB - Objective: To describe the experience with liver irradiation in advanced cases of myelofibrosis with myeloid metaplasia (MMM). Methods: Over a 20-yr period, 14 patients with MMM were treated with a total of 25 courses of liver, abdominal, or abdominal and pelvic irradiation for symptomatic hepatomegaly with (5 patients) or without (9 patients) ascites. All 14 patients had advanced disease and 11 (79%) had previous splenectomy. The median radiation therapy (RT) dose per course was 150 cGy (range 50-1000) administered at a median of six fractions. Four patients received two to six courses. Results: Twelve of the 14 patients (86%) had a transient (median 3 months) subjective response from RT. However, in only 35% of these was there a transient (median 3 months) decrease in palpable liver size. Four of the five patients with ascites experienced a short-term response from RT. Eight of the 13 patients suitable for evaluation (62%) had treatment-associated cytopenia, often in the form of anemia and/or thrombocytopenia. At last follow-up, 10 patients (71%) had died after a median of 7 months (range 0.1-23) and 4 were alive at 3, 20, 33, and 57 months after RT. Conclusions: Low-dose abdominal RT for symptomatic hepatomegaly or ascites associated with advanced-stage MMM is myelosuppressive and provides only temporary and mainly subjective and short-lived relief.

KW - Hepatomegaly

KW - Myelofibrosis with myeloid metaplasia

KW - Radiation therapy

KW - Splenectomy

UR - http://www.scopus.com/inward/record.url?scp=0035141985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035141985&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0609.2001.00342.x

DO - 10.1034/j.1600-0609.2001.00342.x

M3 - Article

VL - 66

SP - 37

EP - 42

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -